Ocuphire Pharma reported oral APX3330 for the treatment of diabetic retinopathy failed to meet the primary endpoint in the phase 2 ZETA-1 trial but achieved key secondary measures.
“Although we did not meet the primary endpoint, we are pleased that the ZETA-1 results on key prespecified endpoints demonstrated positive outcomes with a favorable systemic and ocular safety profile that support our plans to move forward to an end-of-phase 2 meeting with the FDA,” Mina Sooch, MBA, Ocuphire founder and CEO, said in a press release.
The trial comprised 103 participants (Read more...)